Case report:
This is a case of a 2-year-old female
patient who was delivered normally in a private hospital in Amman, Jordan at
37-weeks gestational age. Her birth weight was 3kg, and she was discharged home
after 36 hours of observation. She is the second baby of non-related parents.
She has a 4-year-old healthy sister. The patient was on breast milk feeding in
her first month of life and then a regular formula was added. She was growing
and developing normally, and she received her vaccines according to the
Jordanian national programme. When she was 23 months old, her parents noticed
that she started to be irritable with diarrhoea, with a frequency of
approximately four times a day. She was treated for presumed acute
gastroenteritis, but her symptoms progressed. She developed ataxic gait,
abnormal behaviour, tonic-clonic seizures, and lastly sudden vision loss. Her
parents took her to a private hospital where she was treated for presumed acute
encephalitis and then as autoimmune encephalitis without significant improvement.
After a month of hospitalization, she developed hepatomegaly. Her laboratory
blood tests showed coagulopathy, hypoalbuminaemia, elevated transaminases, and
elevated ammonia. At this stage, she was transferred to Queen Rania Al-Abdullah
Hospital for Children. Her initial exam was the same as above. Her laboratory investigations
initially and on regular follow ups, are shown in Table (1).
Table (I): Baseline and follow up laboratory results.
Test
|
Day 0
|
Day 3
|
Day 7
|
Day 15
|
Day 90
|
Day 180
|
Day 270
|
ALT (IU/l)
|
294
|
492
|
556
|
36
|
29.5
|
The patient missed her clinic appointment
due to COVID-19 pandemic curfew
|
31
|
AST (IU/l)
|
200
|
294
|
441
|
32
|
53.7
|
38
|
Albumin (g/dl)
|
4.8
|
4.04
|
4.6
|
4.93
|
4.27
|
4.5
|
Total protein (g/dl)
|
6
|
5.64
|
5.9
|
6.41
|
6.33
|
7
|
PT (second)
|
22.4
|
20.2
|
-
|
12.3
|
14.7
|
14.7
|
INR
|
1.75
|
1.52
|
-
|
0.92
|
1.09
|
1.09
|
PTT (second)
|
29.9
|
31.6
|
-
|
20.1
|
29.7
|
29.7
|
Ammonia (µg/dl)
|
644
|
12
|
432
|
16.3
|
139.8
|
113
|
Lactate (mg/dl)
|
18
|
26.4
|
29
|
18.4
|
33.8
|
15
|
Radiographic studies were reviewed. There
was hepatomegaly on abdominal ultrasound with normal echotexture, normal brain
CT scan, and normal brain MRI. At this stage the differential diagnosis
included autoimmune hepatitis, autoimmune encephalitis, metabolic liver disease,
neurometabolic disorder and urea cycle disorder. Therefore a metabolic workup,
including serum aminoacids, urine organic acids, and acylcarnitines, was sent
to the laboratory, and the patient was started on a protein-restricted diet
with ammonia scavengers and l-arginine supplements. Her symptoms improved by
this management. Her vision returned within a week, and her gait returned to
normal after 3 weeks. Her ammonia level, surprisingly, returned to lower than
the normal ranges after 3 days, and the ammonia scavengers were stopped.
Unfortunately, her ammonia level rose again to four times above the upper
normal range, and the patient again started to have abnormal behaviour.
Thereafter, ammonia scavengers were restarted, with better clinical results
according to her symptoms and general physical exam. On the other hand, the
metabolic screen was normal on three occasions, so whole exome sequencing (WES)
was used for the diagnosis. WES was performed in a private laboratory, which
was positive for a splicing mutation, class 1 pathogenic, heterozygous,
NM_000531.5:c.1006-1G>A on the OTC gene on the X chromosome, which confirmed
the diagnosis of X-linked OTC deficiency (7).
The patient is now maintained on a
protein-restricted diet, ammonia scavengers and l-arginine supplements. She is
regularly followed at the Metabolic Clinic and her clinical course is improving.
DISCUSSION
This
case illustrates the challenges that medical providers face to reach a
diagnosis in rare disorders, including IEM and further difficulties that may be
met in heterozygous females with X-linked recessive inherited disorders. For
example, in the above-mentioned case, hyperammonaemia may present with
encephalopathy and hepatopathy. However, hepatopathy, from any other cause, may
also present with hyperammonaemia and encephalopathy (9, 10, 14).
A positive history or a positive family
history of unexplained recurrent illnesses or deaths usually increases the
suspicious of IEM. Laboratory biochemical findings such as hyperammonemia,
hyperlactatemia, abnormal serum aminoacid profile, abnormal findings in the
acylecarnetins and the newborn screening tests and abnormal organicacids in the
urine in most cases narrow the differential diagnosis of a physician sometimes
make a specific diagnosis. Functional dietary, exercise and other tests
challenging a pathway of a metabolite can also help. Confirmed IEM diagnosis is
reached via specific enzymatic assay or genetic mutation detection. (18).
The hallmark of urea cycle disorders is
hyperammonimic encephalopathy, therefore any patient who is suspected to have
hyperammonemia should be treated urgently. The principles of emergency
treatment include; exogenous protein restriction with argenine supplements (argenine
is contraindicated if arginase deficiency is suspected), ensure high energy
supply from lipids and carbohydrates and ammonia reduction pharmacologically or
with dialysis. Maintenance management depends on the specific diagnosis. Dietary
protein restriction to the recommended daily requirement according to FAO/WHO
is useful with vitamins and trace elements supplements to avoid dietary
deficiencies. Hyperammonemia can be managed with ammonia scavengers such as
sodiumbenzoate , sodium phenylbuterate and glycerol phenylbuterate. Carglumic
acid ,which stimulates the urea cycle, is curative in cases of NAGS deficiency and
it can stimulate the urea cycle. L-argenine and l-citrulline supplements stimulate
the residual function of the urea cycle. (9, 10)
Summer,et al (5)
summarized the incidence of the urea cycle disorders as shown in table (II).
Table II: The incidence of all urea cycle disorders.
All UCDs
|
1/35,000
|
NAGS
|
<1/2,000,000
|
ASL
|
1/218,750
|
CPS1
|
1/1,300,000
|
ARG
|
1/950,000
|
OTC
|
1/56,500
|
Citrin
|
<1/2,000,000
|
ASS
|
1/250,000
|
HHH
|
<1/2,000,000
|
ARG: Arginase deficiency, ASL: Arginosuccinate layase deficiency, ASS:
Arginosuccinate synthetase deficiency, CPS1: Carbomylphosphatase 1 deficiency,
Citrin: Aspartate/Glutamate antiporter deficiency, HHH:
Hyperammonemia/Hyperornithinemia/Homocitrulinemia syndrome, NAGS: N-acetylglutamate
synthase deficiency, OTC: Ornithine transcarbamylase deficiency, UCDs: Urea cycle
disorders.
OTC deficiency is the most common urea
cycle disorder, which is usually fully expressed in newborn males and expressed
in variable severities in heterozygous females. The wide range of presentations
in females that are heterozygous carriers makes the diagnosis challenging,
especially without a positive family history or a previously affected sibling.
Symptoms range from lethal newborn presentation to asymptomatic carriers whose
symptoms appear only with stressful situations, such as acute illness, surgery,
or vaginal delivery (3, 12). Thereafter, the differential diagnosis of OTC
deficiency in females is delayed in most cases, as in the above-mentioned case.
As Pinto
et al. (15), both mucopolysacharidosis II (MPS II) and fabry disease
are X-linked disorders that show wide spectrum expression in heterozygous
females. It is thought that these differences could be explained by
cross-correction mechanisms and skewed X-inactivation.
The X chromosome lyonization phenomenon
leads to mosaic cells, i.e. some cells with a non-mutant X chromosome and
others with a mutant one). This mosaic usually leads to biological advantages,
but with no guarantee of this (15, 16).
Although the X-inactivation mechanism was
discovered about 50 years ago, X-linked diseases show a continuum of penetrance
pattern due to an unclear mechanism, which requires further scientific information
about cell biology to allow us to provide better informed genetic counselling
to affected families (17).
Conclusion
Physicians find rare disorders, in general,
difficult to diagnose due to their unusual presentations and the need for
specific laboratory investigations. Newborn screening programmes can be
manipulated for each country according to the disease prevalence, available
treatment options and the severity at presentation. Awareness of other IEMs,
which were not included in screening programmes, missed in the screening
programme and/or were normal at screening, should be increased among general
physicians and paediatricians in order to make a rapid diagnosis and start treatment,
so as to ensure better outcome. On the other hand, unsolved cases and patients
with unusual presentations or disease progression should be referred to
specialized centres that can deal with these patients. Genetic assessment and
diagnosis are nowadays mandatory to establish the diagnosis and to offer better
counselling to the family.
Acknowledgment
We
would like to express our great appreciation and gratitude to both parents who permitted
us to publish their daughter’s case and to the officials at Queen Rania
Al-Abdullah Hospital for Children for their effort collecting and analysing the
data for this case study.
REFERENCES
1 .Nagata, N., Matsuda, I., Oyanagi, K. (1991). Estimated frequency of urea cycle enzymopathies in Japan. American Journal of Medical Genetics, 39, 228–229.
2 .Brusilow, S., & Maestri, N. E. (1996). Urea cycle disorders: Diagnosis, pathophysiology, therapy. In L. A. Barness, D. C. DeVivo, M. M. Kaback, G. Morrow, F. A. Oski, & A. M. Rudolph (Eds.), Advances in paediatrics (p.127). Chicago: Mosby.
3 .Gyato, K, Wray, J, Huang, Z. J.,Yudkoff, M., & Batshaw, M. L. (2004). Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Annals of Neurology, 55, 80–86.
4 .Walker, V. (2009). Ammonia toxicity and its prevention in inherited defects of the urea cycle. Diabetes, Obesity and Metabolism, 11, 823–835.
5 .Summar, M. L., Koelker, S., Freedenberg, D., et al. (2013). The incidence of urea cycle disorders. Molecular Genetics and Metabolism, 110, 179–180.
6 .Caldovic, L., Abdikarim, I., & Narain, S. (2015). Genotype-phenotype correlations in ornithine transcarbamylase deficiency: A mutation update. Journal of Genetics and Genomics, 42, 181–194.
7 .McCullough, B., Yudkoff, M., & Batshaw ML. (2000). Genotype spectrum of ornithine transcarbamylase deficiency: Correlation with the clinical and biochemical phenotype. American Journal of Medical Genetics, 93, 313–319.
8 .Häberle, J., Boddaert, N., Burlina, A., et al. (2012). Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet Journal of Rare Diseases, 7, 32.
9 .Häberle, J., Burlina, A., Chakrapani, A., et al. (2019) Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. Journal of Inherited Metabolic Disease, 42, 1192–1230.
10 .Häberle, J., & Rubio, V. (2016). Disorders of the urea cycle and related enzymes. In J.M. Saudubray,M. Baumgartner, & J. Walter (Eds.),Inborn metabolic diseases(pp. 295-308).Berlin: Springer-Verlag.
11 .Meastri, N. E., Lord, C., Glynn, M., Bale, A., & Brusilow, S. W. (1998). The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine, 77, 389–397.
12 .Ahrens, M.J., Berry, S. A., Whitley, C. B., Markowitz, D. J., Plante, R. J., & Tuchman M. (1996). Clinical and biochemical heterogeneity in females of a large pedigree with ornithine transcarbamylase deficiency due to the R141Q mutation. American Journal of Medical Genetics, 71, 311–315.
13 .Batshaw, M. L., Roan, Y., Jung, A. L., Rosenberg L. A., & Brusilow, S. W. (1980). Cerebral dysfunction in asymptomatic carriers of ornithine transcarbamylase deficiency. New England Journal of Medicine, 302, 482–485. http://dx.doi.org/10.1056/NEJM198002283020902
14 .Khan, A., Ayub, M.,&Khan, W. M. (2016).Hyperammonemia isassociated with increasing severity of both liver cirrhosis and hepatic encephalopathy.International Journal of Hepatology, 2016, 6741754. http://dx.doi.org/10.1155/2016/6741754
15 .Pinto, L. L., Vieira, T. A., Giugliani, R., & Schwartz, I. V. (2010). Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.Orphanet Journal of Rare Diseases, 5, 14. http://dx.doi.org/10.1186/1750-1172-5-14
16 .Uehara, S., Hashiyada, M., Sato, K., Sato, Y., Fujimori, K., &Okamura, K. (2001). Preferential X-chromosome inactivation in women with idiopathic recurrent pregnancy loss. Fertility and Sterility, 76, 908–914.
17 .Dobyns, W. B., Filauro, A., Tomson, B. N., Chan, A. S., Ho, A. W., Ting, N. T., et al. (2004). Inheritance of most X-linked traits is not dominant or recessive, just X-linked. American Journal of Medical Genetics Part A, 129A, 136–143.
18 .Häberle, J., & Rubio, V. (2016). Diagnostic procedures. In J.M. Saudubray, M. Baumgartner, & J. Walter (Eds.), Inborn metabolic diseases(pp. 91-109).Berlin: Springer-Verlag.